Cancer Research is one of the most talked about subjects in modern day times. The deadly disease is so widespread that just about everyone on earth has been affected in some form or way. Cancer medicines, treatments, procedures, and methods have changed throughout the years and there is one company that is currently leading the charge. Seattle Genetics is a biotechnology company led by Clay Siegall, that focuses on the development and commercialization of Antibody Based Therapies. This crucial fight against cancer is constantly evolving and with these specific therapies present, cancer is experiencing a devastating blow. Antibody Drug Conjugates are the stars of this style of therapy thanks to their affects on cancer and the human body. (ADCs) are highly affective because they deliver a devastating injection of cancer killing agents right into cancer cells.
This biotech company is led by Dr. Clay Siegall. Siegall has a huge resume of success within the industry, but it’s his strong passion to help others which sets him apart from his contemporaries. Dr. Siegall has a Ph.D in Genetics from George Washington University as well as a (BS) in Zoology from the University of Maryland. The question may be asked “is clay siegall over qualified?” When it comes to cancer I’d think it’s better to be over qualified than underqualified. Dr. Siegall is no novice to the field and has many years of experience in the business long before Seattle Genetics was founded.
The good doctor has worked with some of the most prestigious institutes in the world such as Bristol-Meyers Squibb and The National Institute of Health. With the huge success of Seattle Genetics (ADCETRIS) Technology, the company has multiple strategic licenses with organizations like AbbVie, Genentech, Pfizer, and GlaxoSmithKline. The future looks bright thanks to Clay Siegall and the leading cancer research center of Seattle Genetics.